A British cervical cancer trial has shown that a chemotherapy drug given at a specific time can reduce the mortality rate by 35%. The trial, funded by Cancer Research UK, involved 500 female patients aged between 26 and 72. The patients were randomized into two groups, one receiving chemoradiation therapy alone and the other receiving induction chemotherapy followed by the same chemoradiation therapy. At the end of a 5-year follow-up, 80% of the patients who received the combination treatment were still alive, with 73% showing no signs of the cancer returning. The trial concluded that this combination of drugs and therapy should be the new standard of treatment.